PolyTherics provides site specific conjugation technologies and novel polymers to enable the development of better biopharmaceutical drugs through PEGylation and protein, peptide, antibody drug conjugation (ADC). These technologies are applied to optimise PK/PD (pharmacokinetics/pharmacodynamics), produce protein-drug conjugates and novel bispecific product formats, and achieve targeted delivery through carbohydrate and protein interactions